Research project
Hypermarker
Developing a clinical decision support tool that will make it easier for clinicians to personalise the treatment for patients with high blood pressure. The team is using AI, deep learning methods and patient cohort data from 11 European countries.
- Duration
- 2023 - 2026
- Contact
- Thomas Hankemeier
- Funding
- EU Horizon 2.1 ID 101095480
- Partners
HYPERMARKER is a four-year international research project that received a 10 million euro grant from Horizon Europe and UK Research and Innovation. Starting in January 2023, the project aims to unleash the potential of pharmacometabolics to provide ‘smart’ prescription of antihypertensive therapy, based on large-scale cohorts from 11 European countries, with validation in a randomised control trial. The primary outcome will be a metabolic profile-based clinical decision support tool that uses advanced data analytics and robust AI algorithms to personalise and optimise the choice of blood pressure treatment. As CVDs are prevalent among patients with hypertension, the effectiveness of pharmaceuticals prescribed for hypertension will also be studied in heart failure (HF), acute coronary syndrome (ACS) and atrial fibrillation (AF).
The team in Leiden will analyse 4,000 plasma samples from patients with high blood pressure to further improve medication for “the silent killer”, i.e., hypertension. This pharmacometabolomics approach, which optimizes a treatment with the metabolic type of a patient, will be the blueprint for the clinical lab of the future. This approach will help personalise treatments not only for high blood pressure but also for other diseases because a citizen’s full physiological state is considered.